healioslabs

Picture1
Menu

capabilities

DOSAGE FORM EXPERTISE

At Healios, we take pride in advancing healthcare through innovative formulation development. Our expertise spans a wide range of dosage forms, from simple oral solution to complex parenteral injections. By combining scientific rigor with patient-centric design, we create formulations that enhance efficacy, improve patient compliance, and accelerate time-to-market.

8

Topicals

Ointments, creams, lotions, gels, foams, patches, balms, salves, and emulsions

7

Transdermals

Matrix patches, Microneedles, transdermal gels

4

Inserts

Vaginal insert, Sublingual films, Rectal Suppositories

5

Ophthalmics

Eye drops, ocular gels, ocular inserts, suspensions

3

Otics

Ear drops, otic solutions, suspensions, and gels for targeted relief.

2a

Nasal

Nasal sprays, gels, powders, and solutions for rapid systemic absorption.

6

Injectables

Solutions, suspensions, emulsions, pre-filled syringes, and lyophilized formulations.

1

Liquid Orals

Syrups, solutions, suspensions, emulsions, and elixirs optimized for taste and bioavailability.

Comprehensive Expertise in Drug Modalities

Redefining the way we develop drugs is a very detailed work using innovative strategies. We are capable of producing vast portfolio of drug modalities, carefully engineered to address distinct therapeutic needs.

1 (1)

Small Molecules

Poor solubility and stability of small molecules are often problems hindering bioavailability and therapeutic efficacy. The physicochemical properties of these compounds can interfere with their absorption, and therefore their efficacy. By utilizing advanced formulation technologies, such as solid dispersion techniques and lipid based delivery systems, Healios improves solubility and stability and thus bioavailability and therapeutic action.

2 (1)

Synthetic Peptides

Formulation of synthetic peptides is hampered by rapid enzymatic degradation and limited oral bioavailability. For stable biological activity, formulation techniques have to be precise. In the case of Healios, we utilize protective delivery systems such as liposomes or nanoparticles to prolong the stability of the manipulated genes and enable targeted delivery. Peptide synthesis and characterization expertise allow us to design robust formulations that retain integrity and functional properties.

3 (1)

Highly Potent Active Ingredients (HPAIs)

HPAIs are potent for which reason there are strict safety protocols for its handling and formulation. To prevent exposure risks some of these compounds are quite unique and require special containment measures as well as very careful process control. Healios follows best practice in process validation and containment, through use of state of the art technology, facilitating the safe and effective formulation of HPAIs whilst maintaining product integrity and operator safety.

4 (1)

Oncology

The challenge of oncology therapeutics is to target malignancies without also attacking healthy tissue. Due to the complexity of tumor biology, there is a requirement for a nuanced approach for designing a drug. Biomarker driven strategies are used by Healios to develop targeted therapies delivering drugs to target organs with reduced systemic toxicity. Using our skills in molecular pharmacology, we build formulations that improve therapeutic indices, thus leading to better patient outcomes.

By commitment to scientific rigor and innovative new methodologies, we create drug modalities that make a real difference in healthcare. Join us along our pioneering journey to transform drug development with the next generation of therapeutic products.

SPECIAL DEVELOPMENT PROGRAMS

With a commitment to scientific rigor and inventive methodologies, we at Healios are advancing specialty development. We customize our programs specifically to address the various complexities seen in the pharmaceutical landscape and push progress in key domains.

Value Added Medicine—505(b)(2):

With extensive knowledge of the FDA’s 505(b)(2) regulatory route, we combine historical and contemporary data sets to speed developmental and regulatory approvals of new therapeutics. It helps you improve your strategic market entry and cut your time-to-launch.

We are experts in the design of synergistic drug–device combinations where a combination of pharmacological efficacy and patient adherence is achieved. We use a multidisciplinary model to harmonize our therapeutic modalities into the most optimal clinical outcomes.

HPAIs are potent for which reason there are strict safety protocols for its handling and formulation. To prevent exposure risks some of these compounds are quite unique and require special containment measures as well as very careful process control. Healios follows best practice in process validation and containment, through use of state of the art technology, facilitating the safe and effective formulation of HPAIs whilst maintaining product integrity and operator safety.

Using scientifically driven biowaiver strategies based on existing biopharmaceutical criteria, we deliver bioequivalence assessments in a much shorter time frame, while abiding by the regulatory mandates and maintaining product integrity.

Using advanced analytical techniques and molecular modelling, we facilitate repurposing of existing compounds. This new approach provides a means to identify new therapeutic applications and augment treatment paradigms, and broaden the patient community.

We are a formulation team that can formulate New Chemical Entities using state of the art formulation science and sophisticated delivery technologies to translate breakthroughs into marketable products.

With strict efficacy and safety standards, we address the challenges with complex generics. With our focus on quality and cost effectiveness we are able to offer patients with accessible therapeutic alternatives.

Personalized drug release technologies, solubility enhancement strategies and bespoke dosing regimens applied to our formulations help align them with the needs of the patient to obtain optimal therapeutic response and improve adherence.

Our carefully designed release formularies employ advance delivery systems to deliver the optimal pharmacokinetic profiles, i.e., provide high drug levels at the site of action and minimize side effects.

We employ advanced biopharmaceutical strategies to increase bioavailability and absorption kinetics of therapeutic agents and thereby enable the normalization of therapeutic agents to their optimal plasma concentrations for optimal patient outcomes.

We use scientific rigorous methodology to build our formulations including comprehensive stability testing and pharmacokinetics reaction modelling. Optimization of drug delivery systems is a major focus for us as we address the unique molecular characteristics of different dermatological conditions.



At Healios, we’ve set a path for innovation driven by scientific excellence in specialty development. Join us! Let’s build this together and change healthcare so we can improve the lives of patients all around the world!

Advanced Drug Delivery Solutions Across Multiple Routes

We are a leading company in new generation drug delivery systems with more than 25 years experience in our field.  Safety, effectiveness and the appearance of the final product is what we are mainly concerned with.

Dermal Delivery

We formulate and develop a range of topical and transdermal products such as creams, gels, aerosol and patches utilizing sophisticated models to achieve improved formulations.

Our competency in respiratory products includes nasal spray, nasal drops that are enhanced by specialized performance models.

We have developed effective ocular formulations (drops and ointment) with proprietary models to improve trans-corneal penetration.

We design optimized rectal and vaginal delivery formulations, using bespoke models of performance to support clinical efficacy.

We have solutions for both outer and middle ear with targeted drops and lotions, all based on customized performance models.

Using proprietary models, we have developed novel technologies for both ungual and transungual drug delivery and lead in biowaivers to create an easier and quicker path to market access.